-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Critical Contrast: Longboard Pharmaceuticals (NASDAQ:LBPH) Vs. Midatech Pharma (NASDAQ:MTP)
Critical Contrast: Longboard Pharmaceuticals (NASDAQ:LBPH) Vs. Midatech Pharma (NASDAQ:MTP)
Midatech Pharma (NASDAQ:MTP – Get Rating) and Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.
Profitability
This table compares Midatech Pharma and Longboard Pharmaceuticals' net margins, return on equity and return on assets.
Get Midatech Pharma alerts:Net Margins | Return on Equity | Return on Assets | |
Midatech Pharma | N/A | N/A | N/A |
Longboard Pharmaceuticals | N/A | -36.88% | -34.73% |
Analyst Ratings
This is a summary of recent ratings and price targets for Midatech Pharma and Longboard Pharmaceuticals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Midatech Pharma | 0 | 0 | 0 | 0 | N/A |
Longboard Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
Earnings and Valuation
This table compares Midatech Pharma and Longboard Pharmaceuticals' gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Midatech Pharma | $800,000.00 | 64.01 | -$7.51 million | N/A | N/A |
Longboard Pharmaceuticals | N/A | N/A | -$27.80 million | ($2.13) | -1.68 |
Midatech Pharma has higher revenue and earnings than Longboard Pharmaceuticals.
Institutional and Insider Ownership
3.4% of Midatech Pharma shares are owned by institutional investors. Comparatively, 55.5% of Longboard Pharmaceuticals shares are owned by institutional investors. 6.8% of Longboard Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Midatech Pharma has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
Summary
Midatech Pharma beats Longboard Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About Midatech Pharma
(Get Rating)
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
About Longboard Pharmaceuticals
(Get Rating)
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
米达泰克制药(纳斯达克:MTP-GET评级)和长板制药(纳斯达克:LBPH-GET评级)都是小盘医疗公司,但哪一家是优势业务?我们将根据两家公司的风险、收益、盈利能力、分析师建议、机构所有权、估值和股息的强弱进行比较。
盈利能力
此表比较了Midatech Pharma和Longboard PharmPharmticals的净利润率、股本回报率和资产回报率。
到达Midatech Pharma警报:净利润率 | 股本回报率 | 资产回报率 | |
Midatech Pharma | 不适用 | 不适用 | 不适用 |
长板制药 | 不适用 | -36.88% | -34.73% |
分析师评级
这是MarketBeat报道的Midatech Pharma和Longboard PharmPharmticals最近的评级和目标价摘要。
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Midatech Pharma | 0 | 0 | 0 | 0 | 不适用 |
长板制药 | 0 | 0 | 3. | 0 | 3.00 |
收益和估值
该表格比较了Midatech Pharma和Longboard PharmPharmticals的毛收入、每股收益和估值。
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Midatech Pharma | 800,000美元 | 64.01 | -751万美元 | 不适用 | 不适用 |
长板制药 | 不适用 | 不适用 | -2,780万元 | (2.13美元) | -1.68 |
Midatech Pharma的收入和收益高于Longboard PharmPharmticals。
机构和内部人持股
Midatech Pharma 3.4%的股份由机构投资者持有。相比之下,长板制药55.5%的股份由机构投资者持有。朗博制药6.8%的股份由公司内部人士持有。强大的机构持股表明,对冲基金、大型基金管理公司和捐赠基金相信,一只股票的长期表现将好于大盘。
风险和波动性
Midatech Pharma的贝塔系数为2.24,这意味着其股价的波动性比标准普尔500指数高124%。相比之下,Longboard PharmPharmticals的贝塔系数为0.7,这意味着其股价的波动性比标准普尔500指数低30%。
摘要
Midatech Pharma在比较两只股票的9个因素中有5个超过了Longboard PharmPharmticals。
关于Midatech Pharma
(获取评级)
Midatech Pharma plc是一家药物输送技术公司,专注于在英国、欧洲其他地区和国际上进行药物研究和开发。该公司正在开发MTX110,这是一种直接递送治疗弥漫性桥脑胶质瘤、髓母细胞瘤和多形性胶质母细胞瘤的药物;MTX114,一种局部应用于牛皮癣的免疫抑制剂;MTD211,一种用于治疗精神分裂症和主要抑郁症辅助治疗的长效制剂;以及MTD219,一种用于降低器官移植排斥反应风险的他克莫司的长效制剂。它还提供药物输送平台,例如Q-Sphera,一种用于缓释药物输送的聚合物微球技术;MidaSolve,一种用于溶解药物的低聚糖纳米技术,以便它们可以液体形式直接和局部地进入肿瘤;以及MidaCore,一种通过使用化疗药物或免疫治疗药物来靶向疾病部位的黄金纳米颗粒。该公司成立于2000年,总部设在英国加的夫。
关于朗博德制药公司
(获取评级)
长板制药公司是一家临床阶段的生物制药公司,专注于开发治疗神经疾病的变革性药物。该公司的主要候选产品是LP352,它正处于1b/2a期临床试验,用于治疗与发育性和癫痫脑病相关的癫痫发作。它的临床前产品候选包括LP659和LP143,后者专注于开发多种神经疾病的治疗方法。该公司前身为Arena NeuroScience,Inc.,并于2020年10月更名为Longboard PharmPharmticals,Inc.Long board制药公司成立于2020年,总部设在加利福尼亚州拉荷亚。
接受Midatech Pharma Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Midatech Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧